If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Treatment with once-daily EFFEXOR® met primary and all secondary efficacy endpoints in outpatient adults with GAD EFFEXOR® was generally well tolerated, consistent with its known safety profile Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025 PITTSBURGH and TOKYO, Oct. 9, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® ...

PITTSBURGH, Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offer (the "Maximum Tender Offer") of its subsidiary Utah Acquisition Sub Inc. ("UAS") for up to an increased maximum aggregate principal amount of $575,003,000 of its outstanding 3.950% Senior Notes due 2026 (the "Maximum Tender Offer Notes") validly tendered and not validly withdrawn at or prior to the Early Tender Date (as defined bel ...

Tender Offer Details - Viatris Inc announced the early tender results of its subsidiary Utah Acquisition Sub Inc's cash tender offer, increasing the maximum aggregate principal amount from $450,000,000 to $575,003,000 for its 3.950% Senior Notes due 2026 [1] - The aggregate principal amount of Maximum Tender Offer Notes validly tendered and not withdrawn by the Early Tender Date was $1,449,950,000, exceeding the Maximum Tender Cap of $575,003,000 [2][3] - UAS will accept tendered notes on a pro rata basis with a proration factor of 39.7% due to oversubscription [3][5] Tender Offer Terms and Timeline - The total consideration for accepted notes will be determined at 10:00 am on September 18, 2024, including an Early Tender Payment of $30 per $1,000 principal amount [4][6] - The Maximum Tender Early Settlement Date is anticipated to be September 20, 2024 [7] - The Maximum Tender Offer will expire at 5:00 pm on October 2, 2024, unless extended or terminated earlier [8] Company Financial Activities - Viatris satisfied and discharged the indenture for its 1.650% Senior Notes due 2025 on September 16, 2024 [11] - Mylan Inc issued a notice of redemption for all outstanding 2.125% Senior Notes due 2025, with redemption expected to be completed by October 16, 2024 [11] Company Overview - Viatris is a global healthcare company combining generics and brands to address healthcare needs worldwide, supplying medicines to approximately 1 billion patients annually [16] - The company has a diverse portfolio of medicines and a global supply chain, with headquarters in the US and global centers in Pittsburgh, Shanghai, and Hyderabad [16]

PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") (CUSIP No. 92556VAB2/ISIN US92556VAB27) and any and a ...

Study Results - Cenerimod demonstrated safety and tolerability in Japanese patients with moderate to severe systemic lupus erythematosus (SLE), with both 2 mg and 4 mg doses showing clinically meaningful improvements in disease activity as measured by mSLEDAI-2K [1][2][3] - The 4 mg dose of cenerimod showed a higher improvement in disease activity compared to the 2 mg dose, with effects persisting long after treatment discontinuation [3] - The results are consistent with global Phase 2 CARE study findings, reinforcing the potential of cenerimod as a treatment for SLE [3][9] Study Design - The ACT-333441 study was a randomized, double-blind, parallel-group, multicenter Phase 2 trial conducted in Japan, involving 17 patients with moderate to severe SLE [2] - Patients were randomized equally to receive either 2 mg or 4 mg of cenerimod once daily, with primary endpoints focusing on safety and tolerability, and secondary endpoints measuring changes in lymphocyte count and efficacy using mSLEDAI-2K [2] About SLE and Cenerimod - Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by overactive T and B lymphocytes, leading to inflammation and organ damage [5] - Cenerimod is an investigational oral S1P1 receptor modulator, offering a novel approach to treating SLE, a disease with limited treatment options [6] Regulatory and Development Status - Cenerimod has received Fast-Track designation from the U.S. FDA, aimed at accelerating development for serious conditions with unmet medical needs [8] - The OPUS program, initiated in December 2022, includes two Phase 3 studies to evaluate cenerimod's efficacy, safety, and tolerability in adult patients with moderate-to-severe SLE [7] Company Overview - Viatris Inc is a global healthcare company focused on providing access to high-quality medicines, supplying approximately 1 billion patients annually [10] - The company combines generics and brands to address global healthcare needs, with a mission to empower people to live healthier lives [10]

Viatris (VTRS) reported $3.8 billion in revenue for the quarter ended June 2024, representing a year-over-year decline of 3.1%. EPS of $0.69 for the same period compares to $0.75 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.82 billion, representing a surprise of -0.49%. The company delivered an EPS surprise of +1.47%, with the consensus EPS estimate being $0.68. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street exp ...

On Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis. Brands net sales reached $2.36 billion, reflecting strong growth in Greater China and the expansion of the company's portfolio in Emerging Markets and JANZ, partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia. Related: Novartis And Viatris Sue ...

Investors are applauding the healthcare company's improving growth story. Shares of Viatris (VTRS 5.90%) were jumping 6% higher as of 11:18 a.m. ET on Thursday after rising as much as 12.4% earlier in the day. The solid gain came after the global healthcare company announced its secondquarter results before the market opened. Viatris reported Q2 revenue of nearly $3.8 billion. Although this reflected a 3% year-over-year decline, it met Wall Street expectations. The company recorded a Q2 net loss of $326 mil ...

Viatris Inc. (VTRS) delivered second-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks Consensus Estimate by a penny. The company recorded adjusted earnings of 75 cents per share in the year-ago quarter. Total revenues came in at $3.79 billion, down 3.1% year over year on a divestiture-adjusted operational basis. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.81 million. The stock is trading up in response to the second-quar ...